SG11201605585SA - Targeted therapy for small cell lung cancer - Google Patents
Targeted therapy for small cell lung cancerInfo
- Publication number
- SG11201605585SA SG11201605585SA SG11201605585SA SG11201605585SA SG11201605585SA SG 11201605585S A SG11201605585S A SG 11201605585SA SG 11201605585S A SG11201605585S A SG 11201605585SA SG 11201605585S A SG11201605585S A SG 11201605585SA SG 11201605585S A SG11201605585S A SG 11201605585SA
- Authority
- SG
- Singapore
- Prior art keywords
- lung cancer
- small cell
- cell lung
- targeted therapy
- targeted
- Prior art date
Links
- 206010041067 Small cell lung cancer Diseases 0.000 title 1
- 208000000587 small cell lung carcinoma Diseases 0.000 title 1
- 238000002626 targeted therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461925143P | 2014-01-08 | 2014-01-08 | |
PCT/US2015/010650 WO2015105995A2 (fr) | 2014-01-08 | 2015-01-08 | Thérapie ciblée pour le cancer du poumon à petites cellules |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201605585SA true SG11201605585SA (en) | 2016-08-30 |
Family
ID=53524469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605585SA SG11201605585SA (en) | 2014-01-08 | 2015-01-08 | Targeted therapy for small cell lung cancer |
Country Status (9)
Country | Link |
---|---|
US (2) | US11046763B2 (fr) |
EP (2) | EP3553087A1 (fr) |
JP (3) | JP6560682B2 (fr) |
CN (1) | CN106456748A (fr) |
AU (2) | AU2015204766B2 (fr) |
CA (1) | CA2935774C (fr) |
ES (1) | ES2728668T3 (fr) |
SG (1) | SG11201605585SA (fr) |
WO (1) | WO2015105995A2 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3656443T (pt) | 2015-01-21 | 2021-12-27 | Univ Leland Stanford Junior | Utilização de agonista trl e agente anti-cd47 para melhorar a fagocitose das células cancerígenas |
US10590182B2 (en) | 2015-02-24 | 2020-03-17 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
WO2017035480A1 (fr) | 2015-08-26 | 2017-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Déplétion accrue de cellules cibles avec un blocage de cd47 et un agoniste de co-stimulation immunitaire |
CN115569192A (zh) * | 2015-12-11 | 2023-01-06 | 小利兰·斯坦福大学托管委员会 | 以双重靶向cd47和egfr来治疗癌症 |
CN107149682B (zh) * | 2016-03-04 | 2022-01-04 | 复旦大学 | 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法 |
EP3442578B1 (fr) * | 2016-04-15 | 2022-02-09 | The Board of Trustees of the Leland Stanford Junior University | Méthodes de détermination et d'obtention de doses thérapeutiquement efficaces d'agents anti-cd47 pour le traitement du cancer |
WO2017193059A1 (fr) * | 2016-05-06 | 2017-11-09 | The Regents Of The University Of California | Systèmes et procédés de ciblage de cellules cancéreuses |
EP3501509A4 (fr) * | 2016-07-15 | 2020-07-08 | Korea Institute of Science and Technology | Nouvelle nanocage et utilisation associée |
WO2018014068A1 (fr) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Polythérapie à base d'ifn de type i atténué-cd47 |
US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
EP3504245A4 (fr) | 2016-08-23 | 2020-04-22 | The Regents of The University of California | Polypeptides chimériques clivables de manière protéolytique et leurs procédés d'utilisation |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
WO2018081448A1 (fr) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Régions charnières d'immunoglobuline modifiées pour réduire l'hémagglutination |
US12049511B2 (en) | 2016-11-10 | 2024-07-30 | Fortis Therapeutics, Inc. | Engineered CD46-specific effector cells and uses thereof in the treatment of cancer |
US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
KR102646468B1 (ko) | 2017-08-02 | 2024-03-11 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd47 항체 및 이의 용도 |
CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
CN107488231B (zh) * | 2017-09-15 | 2020-10-30 | 四川大学 | 抗cd56抗体及其用途 |
JP7391845B2 (ja) | 2017-12-01 | 2023-12-05 | シージェン インコーポレイテッド | Cd47抗体及びがんを治療するためのその使用 |
JP7343528B2 (ja) | 2018-02-12 | 2023-09-12 | フォーティ セブン, インコーポレイテッド | 抗cd47抗体及び抗cd20抗体を使用する抗がんレジメン |
MX2020009774A (es) | 2018-03-21 | 2020-10-08 | Alx Oncology Inc | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. |
CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
CA3102398A1 (fr) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Anticorps bispecifiques diriges contre ceacam5 et cd47 |
WO2019241403A1 (fr) * | 2018-06-13 | 2019-12-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions et procédés pour induire une phagocytose |
US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
WO2020198353A1 (fr) * | 2019-03-26 | 2020-10-01 | Forty Seven, Inc. | Agents multispécifiques pour le traitement du cancer |
KR20220113353A (ko) | 2019-09-18 | 2022-08-12 | 람캅 바이오 알파 에이지 | Ceacam5 및 cd3에 대한 이중특이적 항체 |
WO2021213511A1 (fr) * | 2020-04-24 | 2021-10-28 | Virtuoso Binco, Inc. | Anticorps bispécifiques pour le traitement de maladies associées à cd47 |
AU2021320333A1 (en) | 2020-08-07 | 2023-03-30 | Fortis Therapeutics, Inc. | Immunoconjugates targeting CD46 and methods of use thereof |
WO2023165602A1 (fr) * | 2022-03-04 | 2023-09-07 | Zai Lab (Us) Llc | Utilisation combinée d'anticorps anti-cd47 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489710A (en) | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
US4429008B1 (en) | 1981-12-10 | 1995-05-16 | Univ California | Thiol reactive liposomes |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
JPS59116229A (ja) | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法 |
US4873088A (en) | 1983-09-06 | 1989-10-10 | Liposome Technology, Inc. | Liposome drug delivery method and composition |
US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
WO1994021293A1 (fr) | 1993-03-19 | 1994-09-29 | Duke University | Procede de traitement de tumeurs a l'aide d'un anticorps apte a se lier a la tenascine |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
CA2195557C (fr) | 1994-08-12 | 2006-10-17 | Shui-On Leung | Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques |
BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
FR2741892B1 (fr) | 1995-12-04 | 1998-02-13 | Pasteur Merieux Serums Vacc | Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus |
US20090047213A1 (en) * | 2003-04-14 | 2009-02-19 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
JP2007008895A (ja) * | 2005-07-04 | 2007-01-18 | Chugai Pharmaceut Co Ltd | 抗cd47抗体とインテグリンリガンドとの併用 |
US20070244046A1 (en) * | 2006-03-29 | 2007-10-18 | Margarita Gutova | Identification and characterization of cancer stem cells and methods of use |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
KR20080002341A (ko) | 2006-06-30 | 2008-01-04 | 재단법인서울대학교산학협력재단 | Cd24를 표적으로 하는 암 억제방법 |
CA2669520C (fr) | 2006-11-13 | 2016-07-26 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Procedes de traitement d'un cancer a l'aide de molecules d'arnic dirigees contre cd24 |
CA2965198C (fr) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Marqueurs des cellules souches de la leucemie myeloide aigue |
CA3054220C (fr) | 2008-01-15 | 2022-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Procedes pour manipuler une phagocytose a mediation par cd47 |
EP2111869A1 (fr) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions et procédés pour renforcer le système immunitaire |
KR20110028450A (ko) | 2008-06-16 | 2011-03-18 | 이뮤노젠 아이엔씨 | 새로운 상승 효과 |
JP2012512640A (ja) | 2008-12-19 | 2012-06-07 | ノバルティス アーゲー | 自己免疫および炎症性障害の処置に使用するための可溶性ポリペプチド |
SG168430A1 (en) | 2009-07-22 | 2011-02-28 | Agency Science Tech & Res | Molecular signature of human lung cancer initiating cells |
MX345953B (es) * | 2009-05-06 | 2017-01-27 | Biotest Ag | Usos de inmunoconjugados dirigidos a cd138. |
SI2477648T1 (sl) * | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
KR20120094472A (ko) | 2009-10-21 | 2012-08-24 | 이뮤노젠 아이엔씨 | 신규한 복용 요법 및 치료 방법 |
WO2011079283A1 (fr) | 2009-12-23 | 2011-06-30 | Bioalliance C.V. | ANTICORPS ANTI-EpCAM QUI INDUISENT L'APOPTOSE DE CELLULES CANCÉREUSES ET LEURS PROCÉDÉS D'UTILISATION |
PL3789038T3 (pl) | 2010-05-14 | 2023-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 |
EP2617730B1 (fr) * | 2010-09-17 | 2018-03-07 | National Institute of Advanced Industrial Science And Technology | Marqueur différentiel du cancer du poumon |
EP2723393A4 (fr) * | 2011-06-24 | 2015-02-25 | Ct Se Llc | Conjugués de médicaments à ciblage extracellulaire |
EP2812443B1 (fr) * | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Anticorps anti-cd47 et leurs méthodes d'utilisation |
-
2015
- 2015-01-08 EP EP19163809.7A patent/EP3553087A1/fr active Pending
- 2015-01-08 JP JP2016543230A patent/JP6560682B2/ja active Active
- 2015-01-08 CA CA2935774A patent/CA2935774C/fr active Active
- 2015-01-08 AU AU2015204766A patent/AU2015204766B2/en active Active
- 2015-01-08 CN CN201580012596.XA patent/CN106456748A/zh active Pending
- 2015-01-08 WO PCT/US2015/010650 patent/WO2015105995A2/fr active Application Filing
- 2015-01-08 SG SG11201605585SA patent/SG11201605585SA/en unknown
- 2015-01-08 ES ES15735468T patent/ES2728668T3/es active Active
- 2015-01-08 EP EP15735468.9A patent/EP3092006B1/fr active Active
- 2015-01-08 US US15/107,852 patent/US11046763B2/en active Active
-
2019
- 2019-07-19 JP JP2019133213A patent/JP7316862B2/ja active Active
-
2020
- 2020-11-05 AU AU2020264334A patent/AU2020264334B2/en active Active
-
2021
- 2021-05-21 US US17/327,363 patent/US20210277115A1/en active Pending
- 2021-10-01 JP JP2021162482A patent/JP2021193150A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020264334A1 (en) | 2020-11-26 |
JP7316862B2 (ja) | 2023-07-28 |
JP2021193150A (ja) | 2021-12-23 |
EP3553087A1 (fr) | 2019-10-16 |
EP3092006B1 (fr) | 2019-03-20 |
AU2015204766B2 (en) | 2020-08-13 |
US20160333093A1 (en) | 2016-11-17 |
AU2015204766A1 (en) | 2016-07-14 |
CA2935774A1 (fr) | 2015-07-16 |
EP3092006A4 (fr) | 2017-09-20 |
ES2728668T3 (es) | 2019-10-28 |
CN106456748A (zh) | 2017-02-22 |
WO2015105995A3 (fr) | 2015-11-12 |
JP2017502048A (ja) | 2017-01-19 |
AU2020264334B2 (en) | 2024-06-13 |
US11046763B2 (en) | 2021-06-29 |
WO2015105995A2 (fr) | 2015-07-16 |
EP3092006A2 (fr) | 2016-11-16 |
JP2019196383A (ja) | 2019-11-14 |
US20210277115A1 (en) | 2021-09-09 |
JP6560682B2 (ja) | 2019-08-14 |
CA2935774C (fr) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201605585SA (en) | Targeted therapy for small cell lung cancer | |
ZA201702382B (en) | Combination therapy for cancer | |
IL259017A (en) | Cancer cure is intended | |
IL254705B (en) | Combined treatment for cancer | |
HK1231381A1 (zh) | 癌症組合療法 | |
GB201420139D0 (en) | Factor IX gene therapy | |
IL246607B (en) | Improved cellular preparations and methods for cancer treatment | |
IL246761A0 (en) | Combined cancer treatment | |
GB201407322D0 (en) | Gene therapy | |
ZA201701450B (en) | Small molecule inhibitors for cancer therapy | |
GB201519734D0 (en) | Cancer therapy | |
GB201407837D0 (en) | Methods of cancer therapy | |
HK1254687A1 (zh) | 用於癌症的聯合療法 | |
HRP20210383T8 (hr) | Kombinirana terapija za rak | |
IL247723A0 (en) | Compounds that target cancer stem cells | |
GB201411884D0 (en) | Cancer therapy | |
GB201417819D0 (en) | Agents for cancer therapy | |
GB201511609D0 (en) | Cancer therapy | |
GB201511121D0 (en) | Cancer therapy | |
GB201511120D0 (en) | Cancer therapy | |
GB201515213D0 (en) | Combination therapy for PD-L1 negative tumors | |
GB201409457D0 (en) | Molecules for cancer therapy | |
GB201406529D0 (en) | Molecules for cancer therapy | |
GB201414028D0 (en) | Small molecule inhibitors for cancer therapy | |
GB201411570D0 (en) | Therapy |